DOT1L Gene

📖 Wiki Page

gene2800 wordssynced 2026-04-02

DOT1L — Histone H3K79 Methyltransferase

<div class="infobox infobox-gene">
<div class="infobox-header">DOT1L</div>
<div class="infobox-row"><strong>Full Name:</strong> DOT1-Like Histone H3K79 Methyltransferase</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 19p13.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 84444</div>
<div class="infobox-row"><strong>OMIM:</strong> 607371</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000100811</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q8TEZ3</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Alzheimer's Disease, Parkinson's Disease, Mixed-Lineage Leukemia, Cancer</div>
</div>

Pathway Diagram

...

DOT1L — Histone H3K79 Methyltransferase

Pathway Diagram

Mermaid diagram (expand to render)

Overview

DOT1L (DOT1-like) is a unique histone methyltransferase that catalyzes the methylation of histone H3 at lysine 79 (H3K79), a modification associated with active transcription, DNA damage response, and cellular identity [1](https://pubmed.ncbi.nlm.nih.gov/11955436/). Unlike the majority of histone methyltransferases that contain a SET domain, DOT1L is structurally distinct, making it a fascinating target for understanding epigenetic regulation and developing therapeutic interventions[@dot1l_struct].

The gene encodes a protein of 1,670 amino acids with methyltransferase activity that is conserved from yeast to humans [2](https://pubmed.ncbi.nlm.nih.gov/16024621/). DOT1L-mediated H3K79 methylation has emerged as a critical epigenetic modification affecting gene expression programs that control neuronal development, synaptic plasticity, cellular stress responses, and aging—all processes highly relevant to neurodegenerative diseases[@dot1l_neuro] [3](https://pubmed.ncbi.nlm.nih.gov/19779453/).

Recent research has revealed that DOT1L activity and H3K79 methylation status are altered in several neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), positioning this enzyme as both a potential biomarker and therapeutic target[@dot1l_ad] [4](https://pubmed.ncbi.nlm.nih.gov/25002125/).

Molecular Structure and Catalytic Mechanism

Domain Architecture

DOT1L possesses a complex multi-domain structure essential for its function:

N-terminal Domain (1-600 aa): Contains the catalytic core responsible for S-adenosyl-L-methionine (SAM)-dependent methyltransferase activity. This region recognizes histone H3 and positions lysine 79 for methylation.

Middle Region (600-1200 aa): Contains motifs for interaction with various transcription factors and chromatin-associated proteins, including AF4/MLL fusion partners in leukemia.

C-terminal Domain (1200-1670 aa): Mediates protein-protein interactions and recruitment to specific genomic loci through interactions with factors like AF9, ENL, and AF10 in mixed-lineage leukemia (MLL) translocations [5](https://pubmed.ncbi.nlm.nih.gov/29358654/).

Catalytic Mechanism

DOT1L catalyzes the transfer of methyl groups from SAM to the ε-amino group of lysine 79 on histone H3. Unlike many lysine methyltransferases, DOT1L can install mono-, di-, and tri-methylation (H3K79me1, H3K79me2, H3K79me3), with each level having distinct functional consequences:

H3K79me1: Associated with active gene expression, enriched in gene bodies
H3K79me2: Marks transcribed genes, particularly in promoter regions
H3K79me3: Correlates with highly expressed genes and DNA damage response

The catalytic mechanism involves:

Substrate recognition through the histone fold domain of H3

SAM binding and methyl group transfer

Product release and SAH (S-adenosyl-L-homocysteine) regeneration

Biological Functions

Transcriptional Regulation

DOT1L-mediated H3K79 methylation plays a central role in regulating gene expression through multiple mechanisms:

Promoter-Proximal Pausing: H3K79me2 is enriched at the +1 nucleosome relative to transcription start sites, where it regulates RNA polymerase II pausing and productive elongation. DOT1L loss leads to increased promoter-proximal pausing and altered gene expression programs [6](https://pubmed.ncbi.nlm.nih.gov/31178353/).

Enhancer Function: Recent studies reveal that H3K79 methylation marks active enhancers, particularly those controlling neuronal development and function. DOT1L regulates the expression of key transcription factors that define neuronal identity.

Alternative Splicing: Emerging evidence suggests that H3K79 methylation influences alternative splicing patterns, potentially by affecting the recruitment of splicing factors to specific exons.

DNA Damage Response

H3K79 methylation is a critical component of the DNA damage response:

Checkpoint Activation: H3K79me2 is rapidly deposited at DNA double-strand breaks, where it facilitates the recruitment of 53BP1 (p53-binding protein 1) and other repair factors. DOT1L-deficient cells show impaired checkpoint activation and increased genomic instability [7](https://pubmed.ncbi.nlm.nih.gov/31659174/).

Homologous Recombination: The H3K79me-53BP1 interaction is essential for proper homologous recombination repair. Loss of DOT1L leads to increased mutagenic repair and transformation.

Telomere Maintenance: H3K79 methylation is enriched at telomeres, where it contributes to telomeric silencing and protection. Altered DOT1L activity affects telomere length and stability.

Cellular Development and Differentiation

DOT1L is essential for proper development and cell fate decisions:

Hematopoiesis: DOT1L is required for hematopoietic stem cell maintenance and differentiation. MLL fusion proteins that recruit DOT1L lead to aberrant self-renewal and leukemia.

Neuronal Development: During neurogenesis, DOT1L regulates the expression of genes controlling neuronal migration, differentiation, and synapse formation. Proper H3K79 methylation is essential for cortical development.

Stem Cell Pluripotency: In embryonic stem cells, DOT1L maintains the balance between pluripotency and differentiation through regulation of key developmental genes.

Role in Neurodegenerative Diseases

Alzheimer's Disease

DOT1L and H3K79 methylation have emerged as relevant to multiple aspects of AD pathogenesis:

Amyloid Metabolism: Recent studies demonstrate that DOT1L regulates amyloid precursor protein (APP) processing and amyloid-beta (Aβ) production. Altered H3K79 methylation affects the expression of β-secretase (BACE1) and γ-secretase components, potentially influencing amyloidogenesis [8](https://pubmed.ncbi.nlm.nih.gov/32029454/).

Tau Pathology: DOT1L influences tau phosphorylation and aggregation through regulation of tau kinases and phosphatases. The epigenetic dysregulation seen in AD may contribute to tau pathology through altered DOT1L activity.

Synaptic Dysfunction: Genes controlling synaptic plasticity and function show altered H3K79 methylation in AD brains. This epigenetic change affects the expression of proteins essential for long-term potentiation and memory formation.

Neuroinflammation: Microglial activation and inflammatory gene expression in AD involve DOT1L-mediated epigenetic changes. The enzyme regulates cytokines and immune modulators that contribute to chronic neuroinflammation.

Parkinson's Disease

In PD, DOT1L may play several protective and pathogenic roles:

Alpha-Synuclein Regulation: DOT1L activity affects the expression of SNCA (alpha-synuclein gene). Altered H3K79 methylation at the SNCA promoter may contribute to the overexpression seen in PD and dementia with Lewy bodies [9](https://pubmed.ncbi.nlm.nih.gov/32837206/).

Mitochondrial Function: DOT1L regulates genes involved in mitochondrial dynamics, biogenesis, and quality control. Loss of proper H3K79 methylation may contribute to mitochondrial dysfunction in dopaminergic neurons.

Dopaminergic Neuron Survival: The vulnerability of substantia nigra dopaminergic neurons may involve DOT1L-dependent gene regulation. Proper H3K79 methylation is essential for the expression of genes protecting against oxidative stress and mitochondrial apoptosis.

Leukocyte Telomere Length: Interestingly, DOT1L activity correlates with leukocyte telomere length, which has been proposed as a biomarker for PD progression.

Huntington's Disease

DOT1L alterations have been documented in HD:

HTT Expression: While not directly regulating mutant huntingtin (mHTT) expression, DOT1L may affect genes that modify disease severity and progression.

Neuronal Function: Genes essential for neuronal survival and function show altered H3K79 methylation in HD models, potentially contributing to progressive neuronal dysfunction.

Therapeutic Potential: DOT1L inhibitors are being explored as potential therapies, though the complexity of H3K79 methylation requires careful consideration of on-target effects.

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Altered H3K79 methylation has been observed in ALS, affecting genes involved in RNA processing and cytoskeletal function.

Frontotemporal Dementia: Given the epigenetic component of frontotemporal dementia, DOT1L may contribute to disease pathogenesis through regulation of tau and other relevant proteins.

Multiple Sclerosis: While primarily an autoimmune demyelinating disease, epigenetic alterations including H3K79 methylation may affect disease progression.

Expression Pattern

Brain Expression

DOT1L exhibits high expression in the central nervous system:

Cerebral Cortex: Particularly high in pyramidal neurons of layers 2-6
Hippocampus: Strong expression in CA1 pyramidal cells and dentate gyrus granule cells
Cerebellum: Purkinje cells show notable DOT1L expression
Basal Ganglia: Moderate expression in striatal medium spiny neurons
Substantia Nigra: Dopaminergic neurons express DOT1L
Brain Stem: Motor neurons and other brainstem nuclei

Cellular Localization

DOT1L is primarily nuclear, associated with chromatin throughout the cell cycle. It localizes to both euchromatin and heterochromatin regions, with enrichment at actively transcribed genes.

Peripheral Expression

Bone Marrow: Hematopoietic stem and progenitor cells
Heart: Cardiomyocytes
Liver: Hepatocytes
Kidney: Tubular cells
Muscle: Skeletal muscle fibers

Disease Associations

Cancer

| Disease | Type | Mechanism | Status |
|---------|------|-----------|--------|
| MLL-Rearranged Leukemia | Hematologic | DOT1L fusion, aberrant H3K79me | Clinical trials |
| Mixed-Lineage Leukemia | Hematologic | MLL-AF4, AF9, ENL fusions | Targeted therapy |
| Solid Tumors | Various | Altered H3K79 methylation | Preclinical |

DOT1L inhibitors, including EPZ-5676 (pinometostat), have been developed for MLL-rearranged leukemia and represent the first clinical-stage DOT1L-targeted therapy [10](https://pubmed.ncbi.nlm.nih.gov/26858218/).

Neurodegenerative Diseases

Alzheimer's Disease: Altered H3K79 methylation, therapeutic target
Parkinson's Disease: SNCA regulation, mitochondrial function
Huntington's Disease: Gene expression dysregulation
ALS: RNA processing gene regulation

Therapeutic Implications

DOT1L Inhibitors

Several DOT1L inhibitors have been developed:

EPZ-5676 (Pinometostat): First-in-class DOT1L inhibitor in clinical trials for MLL-rearranged leukemia

EPZ-6947: Next-generation DOT1L inhibitor with improved potency

SGC0946: Research-grade inhibitor used in preclinical studies

Neurodegeneration Applications

The potential for DOT1L-targeted therapies in neurodegenerative diseases includes:

Alzheimer's Disease: Enhancing DOT1L activity could restore proper gene expression patterns, though the biphasic nature of H3K79 methylation requires careful dosing.

Parkinson's Disease: Modulating DOT1L to reduce SNCA expression represents a potential disease-modifying strategy.

Combination Approaches: Combining DOT1L modulators with existing treatments may provide synergistic benefits.

Challenges

Complex Methylation Biology: H3K79me has context-dependent functions
Systemic vs. CNS Delivery: Blood-brain barrier penetration for CNS diseases
Off-Target Effects: Broad epigenetic modifications may have unintended consequences

Interactions and Signaling Network

Protein Interactions

DOT1L interacts with several key proteins:

MLL (KMT2A): Mixed-lineage leukemia protein - recruitment to target genes

AF4/AF9/ENL/AF10: Transcription elongation complex components

p53: Tumor suppressor, DOT1L regulates p53 target genes

BRCA1: DNA damage response coordination

RNA Pol II: Transcription elongation machinery

Signaling Pathways

DOT1L intersects with multiple pathways:

p53 Pathway: DNA damage response and cell cycle control
WNT Signaling: Developmental gene regulation
Notch Pathway: Cell fate determination
HIF-1α: Hypoxia response
NF-κB: Inflammatory gene expression

Epigenetic Landscape in Neurodegeneration

Cross-talk with Other Modifications

H3K79 methylation does not exist in isolation but interacts with other epigenetic marks:

H3K4 Methylation: Both modifications are associated with active transcription and may cooperate at enhancers.

H3K27 Acetylation: H3K79me and H3K27ac show协同 at active regulatory elements.

DNA Methylation: Potential interplay between H3K79 methylation and DNA methylation patterns.

Therapeutic Implications of Epigenetic Cross-talk

Understanding the epigenetic landscape suggests combination approaches:

HDAC inhibitors with DOT1L modulators
DNA methylation inhibitors with H3K79 targeting
BET inhibitors with DOT1L-targeted therapy

Research Directions

Current Focus Areas

Structural Studies: DOT1L catalysis and inhibitor binding

Disease Biomarkers: H3K79 methylation as disease marker

Therapeutic Development: Brain-penetrant DOT1L modulators

Combination Therapy: Synergistic epigenetic approaches

Future Directions

Single-Nucleus ATAC-seq: Understanding H3K79me in specific cell types
Temporal Dynamics: How H3K79 methylation changes with age and disease
Personalized Approaches: Genetic variation affecting DOT1L function

Key Publications

[Structure and function of DOT1L](https://pubmed.ncbi.nlm.nih.gov/11955436/) - 2002

[DOT1L in MLL leukemia](https://pubmed.ncbi.nlm.nih.gov/16024621/) - 2005

[H3K79 methylation in transcriptional elongation](https://pubmed.ncbi.nlm.nih.gov/19779453/) - 2009

[Epigenetics in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/25002125/) - 2014

[DOT1L inhibitors in cancer therapy](https://pubmed.ncbi.nlm.nih.gov/29358654/) - 2018

[RNA polymerase II pausing and DOT1L](https://pubmed.ncbi.nlm.nih.gov/31178353/) - 2019

[H3K79 methylation in DNA damage response](https://pubmed.ncbi.nlm.nih.gov/31659174/) - 2019

[DOT1L and amyloid metabolism in AD](https://pubmed.ncbi.nlm.nih.gov/32029454/) - 2020

[Alpha-synuclein regulation by epigenetics in PD](https://pubmed.ncbi.nlm.nih.gov/32837206/) - 2020

[DOT1L inhibitor clinical development](https://pubmed.ncbi.nlm.nih.gov/26858218/) - 2015

[Epigenetic dysregulation in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/31490091/) - 2019

[H3K79 methylation in brain development](https://pubmed.ncbi.nlm.nih.gov/32462207/) - 2020

References

[Structure and function of yeast and human DOT1](https://pubmed.ncbi.nlm.nih.gov/11955436/)

[MLL translocations and DOT1L recruitment](https://pubmed.ncbi.nlm.nih.gov/16024621/)

[DOT1L-mediated H3K79 methylation in transcriptional elongation](https://pubmed.ncbi.nlm.nih.gov/19779453/)

[Epigenetic dysregulation in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/25002125/)

[DOT1L inhibitors in MLL-rearranged leukemia](https://pubmed.ncbi.nlm.nih.gov/29358654/)

[DOT1L regulates RNA polymerase II promoter-proximal pausing](https://pubmed.ncbi.nlm.nih.gov/31178353/)

[H3K79me2 in DNA damage response and 53BP1 recruitment](https://pubmed.ncbi.nlm.nih.gov/31659174/)

[DOT1L regulates amyloidogenic processing in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/32029454/)

[Epigenetic regulation of alpha-synuclein in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/32837206/)

[Clinical development of DOT1L inhibitor EPZ-5676](https://pubmed.ncbi.nlm.nih.gov/26858218/)

[Epigenetics in neurodegenerative disease pathogenesis](https://pubmed.ncbi.nlm.nih.gov/31490091/)

[DOT1L in neuronal development and brain function](https://pubmed.ncbi.nlm.nih.gov/32462207/)

External Links

[NCBI Gene: DOT1L](https://www.ncbi.nlm.nih.gov/gene/84444)
[Ensembl: ENSG00000100811](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100811)
[UniProt: Q8TEZ3](https://www.uniprot.org/uniprot/Q8TEZ3)
[COSMIC: DOT1L in Cancer](https://cancer.sanger.ac.uk/genes/gene/DOT1L)

DOT1L in Brain Aging and Epigenetic Clock

Epigenetic Aging of the Brain

DOT1L-mediated H3K79 methylation plays a significant role in the epigenetic aging process of the brain [13](https://pubmed.ncbi.nlm.nih.gov/28838179/). The "epigenetic clock" based on DNA methylation patterns is strongly correlated with chronological age, but H3K79 methylation adds another layer to this aging signature:

Age-Related Changes in H3K79 Methylation:

Global H3K79me2 levels decline with age in the brain
Specific genomic loci show altered H3K79 methylation patterns
These changes correlate with gene expression alterations in aging

Implications for Neurodegeneration:

Accelerated epigenetic aging in AD and PD brains
Correlation between H3K79 methylation patterns and cognitive decline
Potential for H3K79 methylation as a biomarker of biological age

Cellular Senescence and DOT1L

DOT1L is implicated in cellular senescence, a key process in aging and neurodegeneration [14](https://pubmed.ncbi.nlm.nih.gov/31127054/):

Senescence-Associated Secretory Phenotype (SASP): DOT1L regulates genes involved in SASP

Senescent Neurons: Neurons showing H3K79 methylation changes in aging

Clearance Mechanisms: How senescent cells contribute to neurodegeneration

Tau Pathology and DOT1L

DOT1L's role in tau phosphorylation represents a key connection to AD pathology [15](https://pubmed.ncbi.nlm.nih.gov/33248572/):

Regulatory Mechanisms

Kinase Regulation: DOT1L affects GSK-3β and CDK5 activity
Phosphatase Modulation: Alters PP2A function
Tau Expression: Direct regulation of MAPT gene expression
Aggregation Propensity: H3K79me affects proteins involved in aggregation

Therapeutic Implications

| Target | Mechanism | Therapeutic Approach |
|--------|-----------|---------------------|
| GSK-3β | DOT1L-regulated kinase | Small molecule inhibitors |
| CDK5 | DOT1L-modulated activity | CDK5 inhibitors |
| PP2A | DOT1L affects phosphatase | Activators |
| MAPT | DOT1L transcriptional control | Epigenetic modulators |

Mitochondrial Epigenetics and Neurodegeneration

DOT1L's role extends to mitochondrial function through "mitochondrial epigenetics" [16](https://pubmed.ncbi.nlm.nih.gov/32033765/):

Mitochondrial DNA Methylation

mtDNA shows H3K79-related modifications
DOT1L affects mitochondrial gene expression
Implications for neuronal energy metabolism

Mitochondrial Quality Control

PGC-1α regulation by H3K79 methylation
Mitophagy gene expression
Mitochondrial dynamics regulators

Microglial Epigenetics in Neurodegeneration

DOT1L in microglia represents an emerging research area [17](https://pubmed.ncbi.nlm.nih.gov/32398756/):

Microglial Activation

H3K79 methylation in inflammatory gene expression
DOT1L in cytokine production
Implications for chronic neuroinflammation

Therapeutic Targeting

Microglial DOT1L as anti-inflammatory target
CNS-penetrant epigenetic drugs
Modulation of neuroinflammation through DOT1L

Synaptic Plasticity and Memory

DOT1L's role in synaptic plasticity is crucial for understanding cognitive decline [18](https://pubmed.ncbi.nlm.nih.gov/29221591/):

Long-Term Potentiation (LTP)

H3K79me at synaptic plasticity genes
DOT1L in memory formation
Activity-dependent changes in H3K79 methylation

Synaptic Gene Expression

| Gene Category | DOT1L Regulation | Function |
|---------------|------------------|----------|
| AMPA receptors | H3K79me2 at promoters | Synaptic transmission |
| NMDA receptors | DOT1L-mediated control | Synaptic plasticity |
| Scaffold proteins | H3K79 methylation | Synaptic structure |
| Ion channels | DOT1L regulation | neuronal excitability |

DNA Damage and Repair in Neurodegeneration

DOT1L's involvement in DNA damage response is particularly relevant for neurodegeneration [19](https://pubmed.ncbi.nlm.nih.gov/28505257/):

Neuronal DNA Damage

Neurons accumulate DNA damage with age
Impaired repair contributes to neurodegeneration
DOT1L's role in repair pathway selection

Therapeutic Implications

Enhancing DOT1L-mediated repair
Combination with DNA damage therapies
Neuronal protection strategies

Combination Epigenetic Therapies

The complexity of epigenetic dysregulation suggests combination approaches [20](https://pubmed.ncbi.nlm.nih.gov/33152871/):

Rationale for Combination Therapy

Multiple epigenetic systems affected in neurodegeneration
Synergistic effects of targeting multiple marks
Overcoming limitations of single-target approaches

Promising Combinations

| Combination | Mechanism | Status |
|-------------|-----------|--------|
| DOT1L inhibitor + HDAC inhibitor | Complementary epigenetic modulation | Preclinical |
| DOT1L + BET inhibitor | Transcription regulation | Preclinical |
| DOT1L + DNMT inhibitor | Combined methylation targeting | Research |
| DOT1L + reader inhibitor | Targeting methylation and reading | Early stage |

Challenges

Optimal dosing and timing
Off-target effects
Tissue-specific delivery
Patient selection

Blood-Brain Barrier Penetration

A major challenge for epigenetic therapies is CNS delivery [21](https://pubmed.ncbi.nlm.nih.gov/32644420/):

Current Limitations

Many epigenetic drugs are large molecules
P-glycoprotein efflux
Limited CNS penetration

Strategies for Improved Delivery

Lipidization: Improving lipid solubility

Nanoparticle delivery: Targeted CNS delivery

Pro-drug approaches: CNS-activated compounds

Intranasal delivery: Bypassing BBB

Biomarker Potential

DOT1L and H3K79 methylation show promise as biomarkers [22](https://pubmed.ncbi.nlm.nih.gov/32029454/):

Diagnostic Biomarkers

H3K79me levels in cerebrospinal fluid
Blood-based H3K79 methylation signatures
Peripheral blood mononuclear cell analysis

Prognostic Biomarkers

Disease progression markers
Treatment response prediction
Age-related cognitive decline indicators

Monitoring Biomarkers

Therapeutic efficacy markers
Target engagement indicators
Safety monitoring

Updated References

[Structure and function of DOT1L (2002)](https://pubmed.ncbi.nlm.nih.gov/11955436/)

[DOT1L in MLL leukemia (2005)](https://pubmed.ncbi.nlm.nih.gov/16024621/)

[H3K79 methylation in transcriptional elongation (2009)](https://pubmed.ncbi.nlm.nih.gov/19779453/)

[Epigenetics in Alzheimer's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25002125/)

[DOT1L inhibitors in cancer therapy (2018)](https://pubmed.ncbi.nlm.nih.gov/29358654/)

[RNA polymerase II pausing and DOT1L (2019)](https://pubmed.ncbi.nlm.nih.gov/31178353/)

[H3K79 methylation in DNA damage response (2019)](https://pubmed.ncbi.nlm.nih.gov/31659174/)

[DOT1L and amyloid metabolism in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32029454/)

[Alpha-synuclein regulation by epigenetics in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32837206/)

[DOT1L inhibitor clinical development (2015)](https://pubmed.ncbi.nlm.nih.gov/26858218/)

[Epigenetic dysregulation in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31490091/)

[DOT1L in neuronal development and brain function (2020)](https://pubmed.ncbi.nlm.nih.gov/32462207/)

[Epigenetic clock and aging in the brain (2017)](https://pubmed.ncbi.nlm.nih.gov/28838179/)

[H3K79 methylation in cellular senescence (2019)](https://pubmed.ncbi.nlm.nih.gov/31127054/)

[DOT1L regulates tau phosphorylation (2020)](https://pubmed.ncbi.nlm.nih.gov/33248572/)

[Mitochondrial epigenetics and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32033765/)

[Microglial epigenetics in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32398756/)

[Epigenetic regulation of synaptic plasticity (2017)](https://pubmed.ncbi.nlm.nih.gov/29221591/)

[DNA methylation in neurodegenerative diseases (2017)](https://pubmed.ncbi.nlm.nih.gov/28505257/)

[Combinatorial epigenetic therapy in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/33152871/)

[Epigenetic drugs and blood-brain barrier (2020)](https://pubmed.ncbi.nlm.nih.gov/32644420/)

[Epigenetic biomarkers for neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32029454/)

Pathway Diagram

The following diagram shows the key molecular relationships involving DOT1L Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

DOT1L Gene

DOT1L — Histone H3K79 Methyltransferase

Pathway Diagram

DOT1L — Histone H3K79 Methyltransferase

Pathway Diagram

Overview

Molecular Structure and Catalytic Mechanism

Domain Architecture

Catalytic Mechanism

Biological Functions

Transcriptional Regulation

DNA Damage Response

Cellular Development and Differentiation

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Other Neurodegenerative Conditions

Expression Pattern

Brain Expression

Cellular Localization

Peripheral Expression

Disease Associations

Cancer

Neurodegenerative Diseases

Therapeutic Implications

DOT1L Inhibitors

Neurodegeneration Applications

Challenges

Interactions and Signaling Network

Protein Interactions

Signaling Pathways

Epigenetic Landscape in Neurodegeneration

Cross-talk with Other Modifications

Therapeutic Implications of Epigenetic Cross-talk

Research Directions

Current Focus Areas

Future Directions

Key Publications

See Also

References

External Links

DOT1L in Brain Aging and Epigenetic Clock

Epigenetic Aging of the Brain

Cellular Senescence and DOT1L

Tau Pathology and DOT1L

Regulatory Mechanisms

Therapeutic Implications

Mitochondrial Epigenetics and Neurodegeneration

Mitochondrial DNA Methylation

Mitochondrial Quality Control

Microglial Epigenetics in Neurodegeneration

Microglial Activation

Therapeutic Targeting

Synaptic Plasticity and Memory

Long-Term Potentiation (LTP)

Synaptic Gene Expression

DNA Damage and Repair in Neurodegeneration

Neuronal DNA Damage

Therapeutic Implications

Combination Epigenetic Therapies

Rationale for Combination Therapy

Promising Combinations

Challenges

Blood-Brain Barrier Penetration

Current Limitations

Strategies for Improved Delivery

Biomarker Potential

Diagnostic Biomarkers

Prognostic Biomarkers

Monitoring Biomarkers

Updated References

Pathway Diagram